Patents Assigned to Finch Therapeutics Holdings LLC
-
Publication number: 20220257672Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: ApplicationFiled: May 3, 2022Publication date: August 18, 2022Applicant: FINCH THERAPEUTICS HOLDINGS LLCInventor: Thomas J. BORODY
-
Publication number: 20220175853Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: ApplicationFiled: February 25, 2022Publication date: June 9, 2022Applicant: FINCH THERAPEUTICS HOLDINGS LLCInventor: Thomas J. BORODY
-
Patent number: 11351205Abstract: The present invention generally relates to therapeutic compositions and methods for treating cancer patients. The compositions and methods can increase efficacy of an anti-cancer therapy, or treat, prevent, or inhibit an oncology-treatment induced condition (OTIC) induced by an anti-cancer therapy. The therapeutic compositions comprise microbial compositions and, optionally, an anti-cancer therapeutic agent. The methods comprise administering a therapeutic composition comprising a microbial composition and administering an anti-cancer therapy.Type: GrantFiled: December 3, 2021Date of Patent: June 7, 2022Assignee: Finch Therapeutics Holdings LLCInventors: Joseph Lobacki, Ulrich Thienel, Zain Kassam, Marina Santiago
-
Publication number: 20220088082Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating primary sclerosing cholangitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.Type: ApplicationFiled: December 3, 2021Publication date: March 24, 2022Applicant: Finch Therapeutics Holdings LLCInventor: Thomas Julius BORODY
-
Publication number: 20220088089Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: December 1, 2021Publication date: March 24, 2022Applicants: Arizona Board Regents on behalf of Arizona State University, Regents of the University of Minnesota, Finch Therapeutics Holdings LLCInventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Publication number: 20220031773Abstract: The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.Type: ApplicationFiled: October 19, 2021Publication date: February 3, 2022Applicant: FINCH THERAPEUTICS HOLDINGS LLCInventor: Thomas Julius BORODY
-
Publication number: 20220031764Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: ApplicationFiled: March 19, 2021Publication date: February 3, 2022Applicant: Finch Therapeutics Holdings LLCInventor: Thomas Julius BORODY
-
Publication number: 20220023356Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C.difficile or the pseudo-membranous colitis associated with this infection.Type: ApplicationFiled: October 7, 2021Publication date: January 27, 2022Applicant: FINCH THERAPEUTICS HOLDINGS LLCInventor: Thomas Julius BORODY
-
Publication number: 20220000940Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating epilepsy, epileptic seizures and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.Type: ApplicationFiled: September 27, 2019Publication date: January 6, 2022Applicant: Finch Therapeutics Holdings LLCInventor: Thomas Julius Borody
-
Publication number: 20220000939Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at ambient temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disorder, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.Type: ApplicationFiled: September 20, 2021Publication date: January 6, 2022Applicant: FINCH THERAPEUTICS HOLDINGS LLCInventor: Thomas Julius BORODY
-
Patent number: 11213549Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating primary sclerosing cholangitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.Type: GrantFiled: October 11, 2017Date of Patent: January 4, 2022Assignee: Finch Therapeutics Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 11207356Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: July 26, 2019Date of Patent: December 28, 2021Assignee: Finch Therapeutics Holdings LLCInventor: Thomas Borody
-
Patent number: 11202808Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: GrantFiled: December 28, 2018Date of Patent: December 21, 2021Assignees: Arizona Board of Regents on Behalf of Arizona State University, Regents of The University of Minnesota, Finch Therapeutics Holdings LLCInventors: James Adams, Rosa Krajmalnik-Brown, Dae-Wook Kang, Michael J. Sadowsky, Alexander Khoruts, Thomas J. Borody
-
Patent number: 11173183Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: August 10, 2018Date of Patent: November 16, 2021Assignee: Finch Therapeutics Holdings LLCInventor: Thomas Julius Borody
-
Patent number: 11166990Abstract: The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.Type: GrantFiled: July 12, 2019Date of Patent: November 9, 2021Assignee: Finch Therapeutics Holdings LLCInventor: Thomas Julius Borody
-
Publication number: 20210330717Abstract: The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.Type: ApplicationFiled: July 2, 2021Publication date: October 28, 2021Applicant: Finch Therapeutics Holdings LLCInventor: Thomas Julius BORODY
-
Patent number: 11129859Abstract: The present disclosure provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: November 3, 2020Date of Patent: September 28, 2021Assignee: Finch Therapeutics Holdings LLCInventor: Thomas Borody
-
Publication number: 20210290688Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating recurrent diverticulitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.Type: ApplicationFiled: June 7, 2021Publication date: September 23, 2021Applicant: Finch Therapeutics Holdings LLCInventor: Thomas Julius BORODY
-
Patent number: 11123377Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at room temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disorder, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.Type: GrantFiled: November 5, 2018Date of Patent: September 21, 2021Assignee: Finch Therapeutics Holdings LLCInventor: Thomas J. Borody
-
Patent number: 11103541Abstract: The present disclosure provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon. compositions of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: September 4, 2020Date of Patent: August 31, 2021Assignee: Finch Therapeutics Holdings LLCInventor: Thomas Borody